Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia.
Fierro
F A
FA
Brenner
S
S
Oelschlaegel
U
U
Jacobi
A
A
Knoth
H
H
Ehninger
G
G
Illmer
T
T
Bornhäuser
M
M
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001596:Benzylamines; D002465:Cell Movement / Q000187:drug effects; D054377:Chemokine CXCL12 / Q000037:antagonists & inhibitors*; D000080027:Cyclams; D006571:Heterocyclic Compounds / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors*; D012008:Recurrence
D000970:Antineoplastic Agents; D001596:Benzylamines; C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D000080027:Cyclams; D006571:Heterocyclic Compounds; D019718:Receptors, CXCR4; C088327:plerixafor